Arcturus Therapeutics earnings date
Want to see ARCT full AI Analyst Report?
Arcturus Therapeutics (ARCT) Q3 2026 Earnings Report
ARCT Q3 2026 EPS Results
- Actual EPS
- -$0.26
- Consensus EPS
- -$0.69
- Beat/Miss
- Beat by +$0.43
- One Year Ago EPS
- -$0.49
ARCT Q3 2026 Revenue Results
- Actual Revenue
- $16.85M
- Expected Revenue
- $8.00M
- Beat/Miss
- Beat by +$8.86M
- YoY Revenue Growth
- +19.07%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/05/2026
- Time
- After Close
- Conference Call
- Thursday, November 5, 2026
Arcturus Therapeutics's next earnings date is estimated for March 11, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was predominantly positive, with encouraging ARCT-810 clinical data, a reported 38-fold LUNAR 2.0 potency improvement, progress in the ARCT-032 and ARCT-2601 programs, expanding pipeline capabilities and a cash runway through year-end 2028. The main negatives were the significant year-to-date revenue decline, higher year-to-date net loss, reduced cash balance and uncertainty around the timing of a potential ARCT-032 Phase III start.
Arcturus expects enrollment in the ARCT-032 Phase II study to be completed by year-end, with Cohort 4 evaluating 10 milligrams administered by inhalation for 12 weeks in up to 20 adults, primarily Class I CF subjects, full Cohort 4 data planned for presentation in the second quarter of 2027, and CF top line data available before the full data presentation; the go/no-go decision timing has not been guided. The company plans to initiate Phase II dosing of ARCT-2601 in the first quarter of 2027, enrolling upwards to 6 subjects ages 12 and older, with top line data in the second half of 2027 and the starting dose being a dose previously tested with 810. Arcturus currently plans to submit an IND for its PKU program in the second half of 2027, expects commercial activities for KOSTAIVE in Europe and the United Kingdom in 2027 while pursuing a partner for the U.S. region, and expects its cash runway to extend through year-end 2028.
- Positive ARCT-810 Phase II Results in OTC DeficiencyARCT-810 demonstrated meaningful biomarker activity at the 0.3 and 0.5 milligram per kilogram dose levels, reducing and/or maintaining first morning fasting ammonia within the normal range, including during increased protein intake. Glutamine levels were reduced in all participants, with the 0.5 milligram per kilogram dose achieving mean glutamine concentrations within the normal range during treatment. The program was generally safe and well tolerated.
- LUNAR 2.0 Delivered 38-Fold Preclinical Potency ImprovementIn nonhuman primates, the next-generation LUNAR 2.0 delivery technology demonstrated a 38-fold improvement in potency compared with the original LUNAR formulation used in ARCT-810. Arcturus stated that this improvement has the potential to enable lower and less frequent dosing and broaden the range of diseases addressed with mRNA therapeutics.
- ARCT-2601 Advancing Toward Phase IIFollowing favorable FDA feedback and clarity from a June Type C meeting, Arcturus plans to initiate Phase II dosing of ARCT-2601 in the first quarter of 2027. The study will evaluate patients with OTC deficiency ages 12 and older, enroll upwards to 6 subjects, and is expected to provide top-line data in the second half of 2027. The starting dose has not been disclosed but will be a dose previously tested with ARCT-810.
- Expansion of the Liver Therapeutics PipelineLUNAR 2.0 is enabling expansion beyond OTC deficiency into additional genetic diseases, including phenylketonuria and gout. For PKU, Arcturus is developing an mRNA therapy designed to enable the liver to produce functional PAH, restore PAH activity, improve phenylalanine metabolism and address the underlying cause of the disease. The company plans to submit a PKU IND in the second half of 2027.
- ARCT-032 Cystic Fibrosis Enrollment ProgressEnrollment in Cohort 4 of the ARCT-032 Phase II cystic fibrosis study accelerated after additional clinical sites were activated in Israel and Turkey. The cohort is evaluating 10 milligrams of ARCT-032 administered by inhalation for 12 weeks in up to 20 adults, primarily Class I CF subjects. Enrollment is expected to be completed by year-end, with full Cohort 4 data planned for presentation in the second quarter of 2027.
- ARCT-032 Safety and Tolerability Remain SupportivePatients in the ARCT-032 study have successfully completed all 12 weeks at the current regimen of 10 milligrams once daily by inhalation. The company stated that it has not observed any severe significant safety events that would trigger study restrictions, discontinuation or a program stop. Unlike certain other programs discussed on the call, Arcturus stated that its protocol has not required daily systemic steroids, routine clinic-based administration or other intensive measures.
- Potential Thermo Fisher Support for ARCT-032Under the collaboration with Thermo Fisher Scientific, a decision to advance ARCT-032 into Phase III would trigger significant contributions from Thermo Fisher. The decision is expected when top-line data is available, before the planned full Phase II data presentation, and remains under Arcturus's control.
- REACH Study Could Support Future CF DevelopmentThe CF Foundation's REACH natural-history study has enrolled hundreds of participants across a wide age span and includes lung-function measures such as FEV1 and LCI, which are also being collected in the ARCT-032 study. Arcturus stated that the data set is progressing and could potentially support discussions with the FDA, reduce the number of patients needed in a future Phase III study and serve as a natural-history control.
- AI and Discovery Capabilities Added Through myNEO AcquisitionArcturus completed the acquisition of myNEO, adding AI-driven capabilities in antigen design, mRNA optimization and target identification. The company said the integration could accelerate pipeline development and create strategic opportunities, including oncology, supported by myNEO's seven years of experience designing neoantigens.
- KOSTAIVE Commercial and Regulatory ProgressKOSTAIVE, Arcturus's self-amplifying mRNA COVID vaccine, continues to be commercialized in Japan through Meiji for the 2026-2027 season. Arcturus also completed the transfer of marketing authorization holder rights in the European Union and United Kingdom from CSL Seqirus to Arcturus, supporting planned commercial activities in Europe and the UK in 2027. The company remains consistent that it would pursue a U.S. partner.
- Positive Pandemic Influenza Vaccine DataResults from the Phase I study of Arcturus's self-amplifying mRNA pandemic influenza vaccine, published in Nature Communications, demonstrated immunological benefits compared with standard of care, a favorable safety profile and the potential for a single-dose pandemic response.
- Reduced Quarterly Research and Development ExpenseResearch and development expenses were $17 million in the third quarter of 2026 versus $23.3 million in the comparable 2025 period, a decrease of approximately 27%. The company attributed the decrease to reduced clinical and manufacturing activities, particularly across the LUNAR-COVID and BARDA programs, together with lower personnel and facility costs.
- Quarterly Net Loss ImprovedThird-quarter net loss was $7.4 million, or $0.26 per share, compared with a net loss of $13.4 million, or $0.49 per share, in the third quarter of 2025. The reported net loss decreased by approximately 45% year over year.
- Cash Runway Through Year-End 2028Arcturus had cash and cash equivalents of $184.8 million as of September 30, 2026, and stated that it maintains a cash runway of over two years through year-end 2028. Management said this supports reaching important clinical and regulatory milestones in the mRNA therapeutic pipeline.
- Multiple Near-Term Pipeline MilestonesThe company expects to complete ARCT-032 enrollment by year-end, provide full Phase II CF data in the second quarter of 2027, initiate ARCT-2601 Phase II dosing in the first quarter of 2027 and report ARCT-2601 top-line data in the second half of 2027.
ARCT Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 11, 2027 | 2026 (Q4) | -0.82- | -1.03 | ― | ― |
| Nov 05, 2026 | 2026 (Q3) | -0.69-0.26 | -0.49 | 46.94% (+0.23) | |
| Aug 06, 2026 | 2026 (Q2) | -1.00-0.84 | -0.34 | -147.06% (-0.50) | |
| May 07, 2026 | 2026 (Q1) | -1.01-0.95 | -0.52 | -82.69% (-0.43) | |
| Mar 03, 2026 | 2025 (Q4) | -0.78-1.03 | -1.11 | 7.21% (+0.08) | |
| Nov 10, 2025 | 2025 (Q3) | -0.90-0.49 | -0.26 | -88.46% (-0.23) | |
| Aug 11, 2025 | 2025 (Q2) | -0.89-0.34 | -0.64 | 46.88% (+0.30) | |
| May 12, 2025 | 2025 (Q1) | -1.18-0.52 | -1 | 48.00% (+0.48) | |
| Mar 06, 2025 | 2024 (Q4) | -0.55-1.11 | -0.32 | -246.88% (-0.79) | |
| Nov 07, 2024 | 2024 (Q3) | -1.22-0.26 | -0.61 | 57.38% (+0.35) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

